; and (ii) the amount (if any) by which— (I) the manufacturer-level billing-code level ASP (as defined in subparagraph (B)) for the manufacturer for the rebate period, exceeds (II) the inflation-adjusted billing-code level ASP (as defined in subparagraph (C)) for the rebate period. (B) Manufacturer-level billing-code level ASP defined In this subsection, the term manufacturer-level billing-code level ASP means, with respect to a manufacturer and a billing code for a rebate period, subject to subparagraph (E)(i), the weighted average sales price (per unit) across all of the National Drug Codes for a manufacturer assigned to the billing code, as determined by the Secretary, for the quarter used to establish payment rates for such Codes during the rebate period. (C) Inflation-adjusted billing-code level ASP defined In this subsection, the term inflation-adjusted billing-code level ASP means, with respect to a billing code and a rebate period, the product of— (i) subject to subparagraph (E)(ii), the average sales price for all National Drug Codes, regardless of manufacturer, assigned to the billing code, as determined by the Secretary, for the calendar quarter beginning January 1, 2017